Moneycontrol PRO
results
Jump to
32 Results Found
  • Ipca Laboratories Q3 PAT may dip 32.4% YoY to Rs 179.6 cr: Prabhudas Lilladher Jan 13, 2022 03:22 PM IST

    Ipca Laboratories Q3 PAT may dip 32.4% YoY to Rs 179.6 cr: Prabhudas Lilladher

    Net Sales are expected to decrease by 2.2 percent Y-o-Y (down 10.8 percent Q-o-Q) to Rs 1,378.3 crore, according to Prabhudas Lilladher.

  • Ipca Laboratories Q2 PAT seen up 7.3% YoY to Rs 292.6 cr: Prabhudas Lilladher Oct 06, 2021 06:00 PM IST

    Ipca Laboratories Q2 PAT seen up 7.3% YoY to Rs 292.6 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 10.7 percent Y-o-Y (down 2.8 percent Q-o-Q) to Rs 1,437.2 crore, according to Prabhudas Lilladher.

  • Ipca Lab Q1 PAT may dip 53.5% YoY to Rs 207.6 cr: ICICI Direct Jul 12, 2021 07:56 PM IST

    Ipca Lab Q1 PAT may dip 53.5% YoY to Rs 207.6 cr: ICICI Direct

    Net Sales are expected to decrease by 13.9 percent Y-o-Y (up 18.6 percent Q-o-Q) to Rs 1321.4 crore, according to ICICI Direct.

  • IPCA Q4 PAT seen up 126.5% YoY to Rs. 194.8 cr: Sharekhan Apr 12, 2021 08:13 PM IST

    IPCA Q4 PAT seen up 126.5% YoY to Rs. 194.8 cr: Sharekhan

    Net Sales are expected to increase by 21.1 percent Y-o-Y (down 7.8 percent Q-o-Q) to Rs. 1,300 crore, according to Sharekhan.

  • IPCA Labs: API capacity constraint almost out of the way Feb 08, 2021 10:32 AM IST

    IPCA Labs: API capacity constraint almost out of the way

    IPCA continues to strive for vertical integration of its formulation production to the level of KSM (Key Starting Material). As of now, more than 60 percent of APIs used for formulations are produced in-house

  • Ipca Labs Q3 PAT seen up 4.9% YoY to Rs. 207.2 cr: Yash Securities Jan 22, 2021 01:02 PM IST

    Ipca Labs Q3 PAT seen up 4.9% YoY to Rs. 207.2 cr: Yash Securities

    Net Sales are expected to increase by 3.8 percent Y-o-Y (down 7.5 percent Q-o-Q) to Rs. 1,259 crore, according to Yash Securities.

  • Ipca Labs Q2 PAT seen up 34% YoY to Rs. 160.2 cr: Emkay Oct 14, 2019 04:12 PM IST

    Ipca Labs Q2 PAT seen up 34% YoY to Rs. 160.2 cr: Emkay

    Net Sales are expected to increase by 12.8 percent Y-o-Y (up 11.3 percent Q-o-Q) to Rs. 1,125.4 crore, according to Emkay.

  • IPCA Laboratories Q1 PAT seen up 34.1% YoY to Rs. 87.9 cr: Prabhudas Lilladher Jul 12, 2019 05:08 PM IST

    IPCA Laboratories Q1 PAT seen up 34.1% YoY to Rs. 87.9 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 14 percent Y-o-Y (up 16.8 percent Q-o-Q) to Rs. 973.5 crore, according to Prabhudas Lilladher.

  • IPCA Laboratories Q4 PAT seen up 106.1% YoY to Rs. 105.8 cr: Prabhudas Lilladher Apr 12, 2019 01:13 PM IST

    IPCA Laboratories Q4 PAT seen up 106.1% YoY to Rs. 105.8 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 24.2 percent Y-o-Y (up 2.5 percent Q-o-Q) to Rs. 970.8 crore, according to Prabhudas Lilladher.

  • IPCA Labs Q3 PAT seen up 1.5% YoY to Rs. 107.2 cr: ICICI Direct Jan 11, 2019 05:36 PM IST

    IPCA Labs Q3 PAT seen up 1.5% YoY to Rs. 107.2 cr: ICICI Direct

    Net Sales are expected to increase by 9.3 percent Y-o-Y (down 7.3 percent Q-o-Q) to Rs. 939.1 crore, according to ICICI Direct.

  • IPCA Labs Q2 PAT may dip 7.3% YoY to Rs. 89.4 cr: ICICI Direct Oct 12, 2018 05:02 PM IST

    IPCA Labs Q2 PAT may dip 7.3% YoY to Rs. 89.4 cr: ICICI Direct

    Net Sales are expected to increase by 10 percent Y-o-Y (up 11.3 percent Q-o-Q) to Rs. 950.5 crore, according to ICICI Direct.

  • IPCA Laboratories Q4 PAT seen up 209.3% YoY to Rs. 83.8 cr: Edelweiss Apr 16, 2018 06:13 PM IST

    IPCA Laboratories Q4 PAT seen up 209.3% YoY to Rs. 83.8 cr: Edelweiss

    Net Sales are expected to increase by 19.4 percent Y-o-Y (down 7.5 percent Q-o-Q) to Rs. 795.1 crore, according to Edelweiss.

  • IPCA Q1 PAT seen up 153% to Rs 95.4 cr: Edelweiss Jul 14, 2016 06:17 PM IST

    IPCA Q1 PAT seen up 153% to Rs 95.4 cr: Edelweiss

    Net Sales are expected to increase by 34.5 percent Q-o-Q (up 10.9 percent Y-o-Y) to Rs 840.4 crore, according to Edelweiss

  • Buy IPCA; it is well valued for long-term investors: Angel Nov 10, 2014 01:48 PM IST

    Buy IPCA; it is well valued for long-term investors: Angel

    Sarabjit Kaur Nangra of Angel Broking says the stock is very well valued at the current prices and adds that the company‘s cautiousness about maintaining its profitability is a positive.

  • Pharma companies revenues to rise 12% in Q3: Anand Rathi Jan 03, 2014 05:34 PM IST

    Pharma companies revenues to rise 12% in Q3: Anand Rathi

    Pharma companies are likely to post 12 percent Y-o-Y revenue growth. However, excluding Wockhardt (FDA issues) and Fortis Healthcare (divestments), revenue growth is expected to be 19 percent Y-o-Y.

  • See India biz grow 15%, exports to rise 25% in H2: Ipca Oct 25, 2013 11:56 AM IST

    See India biz grow 15%, exports to rise 25% in H2: Ipca

    Ipca Labs hopes to continue doing very well in H2FY14 especially in its India formulation business, says ED AK Jain. It is awating USFDA approvals for Indore SEZ which, the company feels will boost its business going forward.

  • May revise guidance upwards post Q2: Ipca Labs Jul 30, 2013 04:11 PM IST

    May revise guidance upwards post Q2: Ipca Labs

    AK Jain, ED, Ipca Labs told CNBC-TV18 that the start of the earnings for the company is very good and down the line maybe after Q2 it may revise the guidance.

  • Pharma cos likely to post 21% EBITDA growth in Q4: MOST Apr 16, 2013 01:30 PM IST

    Pharma cos likely to post 21% EBITDA growth in Q4: MOST

    Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).

  • Improvement in gross margins likely to continue: Ipca Labs Feb 04, 2013 01:11 PM IST

    Improvement in gross margins likely to continue: Ipca Labs

    Last week, Ipca Laboratories reported net profit of Rs 87.89 crore for the quarter ending December 31, 2012 on the back of strong sales across domestic and international markets. AK Jain, ED, Ipca Laboratories told CNBC-TV18 that the margins are going to remain in the regions of around 32 percent plus.

  • Good performance likely from pharma in Q3: Nirmal Bang Jan 12, 2013 03:52 PM IST

    Good performance likely from pharma in Q3: Nirmal Bang

    Nirmal Bang has come out with its earnings estimates for pharmaceutical sector for the quarter ended December 2012. The research firm feels margins of pharma companies may witness YoY expansion owing to rupee depreciation (6 percent YoY).

  • See pharma sector's Q3 topline to grow 22%: Motilal Oswal Jan 12, 2013 11:54 AM IST

    See pharma sector's Q3 topline to grow 22%: Motilal Oswal

    Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.

  • See pharma sector's Q3 adj PAT to grow 26% YoY: P Lilladher Jan 12, 2013 10:57 AM IST

    See pharma sector's Q3 adj PAT to grow 26% YoY: P Lilladher

    Prabhudas Lilladher has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects top-line growth of 24 percent YoY for its coverage universe (excluding one-offs), with EBITDA growth at a robust 24 percent YoY.

  • See pharma sector's margins to dip 314 bps in 3QFY13: Angel Jan 08, 2013 05:10 PM IST

    See pharma sector's margins to dip 314 bps in 3QFY13: Angel

    Angel Broking has come out with earning expectations for pharmaceutical sector for the October-December quarter of 2012. The research firm expects the Indian pharma sector to post lackluster numbers for 3QFY2013 on the sales front.

  • See strong performance by pharma in Mar quarter: KR Choksey Apr 05, 2012 02:45 PM IST

    See strong performance by pharma in Mar quarter: KR Choksey

    According to the report on earnings preview for the quarter ended March 2012, KR Choksey expects the pharma sector will show strong performance in the domestic pharmaceuticals market mainly due to recovery in Indian pharma market.

  • Pharma Q3: New launches, generic drug demand to aid growth Jan 14, 2012 01:37 PM IST

    Pharma Q3: New launches, generic drug demand to aid growth

    Pharmaceutical companies are expected to report healthy 15-25% year-on-year revenue growth in the third quarter, helped by new launches especially in the US and strong demand for generic drugs.

Sections
ISO 27001 - BSI Assurance Mark